Closing Bell: Market Snaps 2-Day Losing Streak, Sensex & Nifty End With Gains, Midcap Stocks Outshine

The Indian stock market snapped its two-day losing streak on Tuesday, January 7, with benchmarks Sensex and Nifty 50 posting strong gains. Broad-based buying, led by heavyweights like Reliance Industries and ICICI Bank, alongside robust performance in the midcap and smallcap segments, fueled the rally.

The Sensex closed at 78,199.11, up 234 points or 0.30%, and Nifty 50 climbed 92 points or 0.39%, finishing at 23,707.90. The Nifty Midcap 100 rose by 502 points or 0.77% to close at 56,869, and the Smallcap Index jumped 1.74%, outperforming the broader indices. The market capitalization of BSE-listed firms surged by Rs 3 lakh crore in a single session, rising to nearly Rs 442 lakh crore from Rs 439 lakh crore.

The rally brought much-needed relief to investors after a two-day decline that had wiped out over 2% of the Sensex and Nifty, driven by foreign institutional investor (FII) outflows and concerns over rising US bond yields and the spread of the Human Metapneumovirus (hMPV).

ONGC was the top Nifty gainer, rising 4% after CLSA upgraded the stock to "High Conviction Outperform." Life insurance stocks like SBI Life and HDFC Life gained up to 3% each. IT stocks like HCLTech, TCS, and Tech Mahindra emerged as top losers.

Biocon jumped 7% on receiving approval from Japan's health authority for its psoriasis treatment drug. Zomato slipped 4% after Jefferies downgraded the stock from "Buy" to "Hold."

Paras Defence soared 10% after securing a license to manufacture light machine guns. MobiKwik surged 10% as its Q2 net loss narrowed sequentially. Akzo Nobel rose 6% on speculation of a potential stake acquisition by Berger Paints. IndiaMART gained 3% after JM Financial upgraded the stock to "Buy" from "Sell."

Ashoka Buildcon added 5% after securing a Rs 1,391 crore order from the National Highways Authority of India (NHAI). Zydus Lifesciences climbed 4% as the company received a USFDA priority review for its new Menkes disease drug.

Equinox India hit a 20% upper circuit after NCLAT approved its merger with Embassy Group. Shakti Pumps hit a record high, gaining 5% as the company announced plans to raise Rs 400 crore via QIP. Info Edge declined 4% despite reporting strong Q3 billings.

The midcap and smallcap segments stole the show with strong gains, outpacing the benchmark indices. Analysts attribute the strength in these segments to healthy buying volumes and positive earnings expectations from mid-sized companies. Stocks like Paras Defence, MobiKwik, and Akzo Nobel contributed to the rally.

The recent sell-off by FIIs, rising US bond yields, and concerns over the spread of the hMPV virus remain potential overhangs for the market. The emergence of hMPV cases in India has evoked comparisons to the early days of the COVID-19 pandemic, creating cautious undertones in the market. Despite Tuesday's gains, market experts warn that sustained recovery will depend on domestic and global cues, particularly FII flows and economic data.

Investors may look for opportunities in midcaps and specific sectors showing resilience, such as energy, insurance, and pharmaceuticals. Amid rising concerns over global and domestic risks, a balanced portfolio with a focus on quality stocks is advisable. As Q3 earnings announcements begin, market direction will likely be influenced by corporate results and forward guidance.